Article
Clinical Neurology
Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari
Summary: This study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to disease-modifying drugs (DMDs) when compared with either DMD-unexposed pregnancies or the general population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Flora Reverchon, Colleen Guillard, Lucile Mollet, Pascal Auzou, David Gosset, Fahima Madouri, Antoine Valery, Arnaud Menuet, Canan Ozsancak, Maud Pallix-Guyot, Severine Morisset-Lopez
Summary: This study reveals a dysregulation of 5-HT7 expression in natalizumab-treated multiple sclerosis (MS) patients, with an increase in 5-HT7 surface expression on T lymphocytes and CD4(+) T cell subsets. Activation of 5-HT7 receptor promotes the production of IL-10, suggesting its protective role in MS.
Article
Immunology
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgun, Tjalf Ziemssen
Summary: This study observed women treated with natalizumab during pregnancy and lactation, finding that most patients did not experience disease activity during gestation and postpartum. Natalizumab concentration in breastmilk was low but detectable sNfL levels were present in most samples.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Sarah Demortiere, Audrey Rico, Adil Maarouf, Clemence Boutiere, Jean Pelletier, Bertrand Audoin
Summary: Comparing two strategies of stopping natalizumab in the first trimester or at conception for women with active multiple sclerosis planning pregnancy, the study found that maintaining natalizumab during the first trimester may reduce the risk of disease reactivation during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Immunology
Jennifer Massey, Katherine Jackson, Mandeep Singh, Brendan Hughes, Barbara Withers, Carole Ford, Melissa Khoo, Kevin Hendrawan, John Zaunders, Benedicte Charmeteau-De Muylder, Remi Cheynier, Fabio Luciani, David Ma, John Moore, Ian Sutton
Summary: This study investigates T cell reconstitution in highly active MS patients for 36 months after AHSCT. The results show that AHSCT induces significant changes in the dominant T cell clones of CD4+ and CD8+ memory T cells. After lymphopenia-induced homeostatic proliferation, clonal attrition occurs. Recovery of thymically-derived CD4 naive T cell repertoire begins at 12 months and continues, but the diversity of the naive populations does not increase compared to baseline, indicating that the principal mechanism for durable remission from MS after AHSCT relates to depletion of putative auto-reactive clones.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
Summary: Ocrelizumab and natalizumab are more effective than cladribine in reducing relapses in patients with relapsing-remitting multiple sclerosis switching from fingolimod. Additional observation time is needed to determine if the statistical difference in annualized relapse rate (ARR) results in long-term disability differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Alyssa A. Toorop, Theo Rispens, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: In pregnant women with very active multiple sclerosis, Natalizumab concentrations gradually decrease during pregnancy, especially in patients with low initial trough concentrations or extended interval dosing. After delivery, Natalizumab concentrations return to pre-pregnancy levels, and patients remain clinically and radiologically stable. MS neurologists should be aware of these changes in drug concentrations during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe L. E. van Kempen, Maurice Steenhuis, Jessica Nielsen, L. G. F. Sinnige, Gert van Dijk, Christiaan M. Roosendaal, Edo P. J. Arnoldus, Elske Hoitsma, Birgit Lissenberg-Witte, Brigit A. de Jong, Bob W. van Oosten, Eva M. M. Strijbis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Gabriel Valero-Lopez, Jorge Millan-Pascual, Francisca Iniesta-Martinez, Juan L. Delgado-Marin, Judith Jimenez-Veiga, Ana B. Tejero-Martin, Adelaida Leon-Hernandez, Joaquin Zamarro-Parra, Ana Morales-Ortiz, Jose E. Meca-Lallana
Summary: This study retrospectively analyzed the use of natalizumab in pregnant women with highly active multiple sclerosis (HAMS). The implementation of the NAP-30 protocol allowed for the continuation of natalizumab treatment during pregnancy, with positive clinical and radiological outcomes and good maternal-fetal safety profile.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Virology
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Domenico Caputo, Mario Clerici
Summary: The detection of miR-J1-5p in urine of MS patients treated with Natalizumab could potentially serve as a biomarker to monitor JCPyV infection and better identify the risk of developing PML. The study found miR-J1-5p in the urine of 28% of patients, even in some cases where JCPyV DNA was not detected in urine or blood. This suggests that miR-J1-5p measurement could be valuable in assessing PML risk in Natalizumab-treated MS patients.
Article
Clinical Neurology
Paula Tomas-Ojer, Marco Puthenparampil, Carolina Cruciani, Maria Jose Docampo, Roland Martin, Mireia Sospedra
Summary: Antigen-induced T-cell exhaustion and T-cell senescence control effector T-cell responses. This study analyzes the markers of CD4+ T-cell senescence in patients with multiple sclerosis (MS) and finds their correlation with markers of neurodegeneration, suggesting their relevance in disease pathogenesis and regulation.
FRONTIERS IN NEUROLOGY
(2022)
Article
Medicine, General & Internal
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher
Summary: The study found that natalizumab treatment can reduce inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients, decrease the levels of white blood cells and proteins, as well as the number of oligoclonal bands in the cerebrospinal fluid. Additionally, the baseline IgM index was found to predict brain volume loss during natalizumab treatment.
Article
Clinical Neurology
Radu Tanasescu, Nanci Frakich, I. -Jun Chou, Perla Filippini, Giulio Podda, Gao Xin, Ranjithmenon Muraleedharan, Oltita Jerca, David Onion, Cris S. Constantinescu
Summary: Natalizumab (NTZ) is a monoclonal antibody that blocks the interaction between activated T cells and B cells with endothelial cells of the central nervous system (CNS), effectively preventing new lesion formation and relapses in multiple sclerosis (MS). This study investigated the effects of NTZ treatment on regulatory T cells (Treg) and other lymphocyte populations in MS patients. The results suggest that NTZ does not have a sustained effect on Treg cells, but it may affect the expression of molecules involved in MS pathogenesis differently from interferon-beta-1a (IFN-β1a).
NEUROLOGY AND THERAPY
(2023)
Article
Clinical Neurology
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli, Giovanni Zanotelli, Mariagiulia Anglani, Margherita Nosadini, Stefano Sartori, Paola Perini, Francesca Rinaldi, Paolo Gallo
Summary: This study evaluated the efficacy and safety of alemtuzumab (ALZ) in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) patients undergoing treatment switch. The results showed that ALZ was more effective in AOMS patients compared to POMS patients after switching from natalizumab (NTZ). However, these findings may underestimate the effectiveness of ALZ in POMS patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Oncology
Elodie Vandenhaute, Carolin Stump-Guthier, Maria Lasierra Losada, Tobias Tenenbaum, Henriette Rudolph, Hiroshi Ishikawa, Christian Schwerk, Horst Schroten, Matthias Duerken, Martin Maerz, Michael Karremann
CANCER CELL INTERNATIONAL
(2015)
Article
Immunology
Henriette Rudolph, Armelle Klopstein, Isabelle Gruber, Claudia Blatti, Ruth Lyck, Britta Engelhardt
EUROPEAN JOURNAL OF IMMUNOLOGY
(2016)
Review
Cell Biology
Tobias Dahm, Henriette Rudolph, Christian Schwerk, Horst Schroten, Tobias Tenenbaum
MEDIATORS OF INFLAMMATION
(2016)
Article
Immunology
Henriette Rudolph, Horst Schroten, Tobias Tenenbaum
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2016)
Article
Immunology
Christian Schwerk, Ruediger Adam, Julia Borkowski, Henriette Schneider, Michael Klenk, Sascha Zink, Natascha Quednau, Nicole Schmidt, Carolin Stump, Anubha Sagar, Barbara Spellerberg, Tobias Tenenbaum, Dirk Koczan, Ludger Klein-Hitpass, Horst Schroten
MICROBES AND INFECTION
(2011)
Editorial Material
Immunology
Henriette Schneider, Gernot Geginat, Michael Hogardt, Alexandra Kramer, Matthias Duerken, Horst Schroten, Tobias Tenenbaum
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2012)
Article
Immunology
Henriette Schneider, Ortwin Adams, Christel Weiss, Ulrich Merz, Horst Schroten, Tobias Tenenbaum
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2013)
Article
Virology
Henriette Schneider, Claudia Ellen Weber, Julia Schoeller, Ulrike Steinmann, Julia Borkowski, Hiroshi Ishikawa, Peter Findeisen, Ortwin Adams, Ruediger Doerries, Christian Schwerk, Horst Schroten, Tobias Tenenbaum
Article
Clinical Neurology
Aiden Haghikia, Annette Langer-Gould, Georg Rellensmann, Henriette Schneider, Tobias Tenenbaum, Birte Elias-Hamp, Sylvia Menck, Julian Zimmermann, Sandra Herbstritt, Martin Marziniak, Tania Kuempfel, Ingrid Meinl, Tatiana Plavina, Ralf Gold, Kerstin Hellwig
Article
Immunology
Marie Wiatr, Carolin Stump-Guthier, Daniela Latorre, Stefanie Uhlig, Christel Weiss, Jorma Ilonen, Britta Engelhardt, Hiroshi Ishikawa, Christian Schwerk, Horst Schroten, Tobias Tenenbaum, Henriette Rudolph
JOURNAL OF NEUROINFLAMMATION
(2019)
Article
Biochemistry & Molecular Biology
Marie Wiatr, Ricardo Figueiredo, Carolin Stump-Guthier, Peter Winter, Hiroshi Ishikawa, Ortwin Adams, Christian Schwerk, Horst Schroten, Henriette Rudolph, Tobias Tenenbaum
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Review
Microbiology
Marie Luckowitsch, Henriette Rudolph, Konrad Bochennek, Luciana Porto, Thomas Lehrnbecher
Summary: The incidence of invasive mold disease (IMD) has been increasing, especially in the form of CNS IMD, which is particularly severe, but there is a lack of data on the incidence of CNS IMD in pediatric patients. Further research is needed on the diagnosis and treatment of CNS IMD, with a particular focus on the safety and efficacy in pediatric patients.
Article
Microbiology
Henriette Rudolph, Katharina Gress, Christel Weiss, Horst Schroten, Ortwin Adams, Tobias Tenenbaum
Summary: This study found that a high viral load in respiratory tract infections may play a role in the development of FS. Factors such as male gender, younger age, and HHV6 positivity may increase the risk of complex FS.